{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:50:17Z","timestamp":1791589817050,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This predefined subgroup analysis of the ESCORT-HT study evaluated the antihypertensive efficacy, organ-protective effects, and safety profile of esaxerenone compared with an angiotensin II receptor blocker (ARB) in patients aged \u226565 years with hypertension on amlodipine, stratified by the presence or absence of type 2 diabetes mellitus (T2DM). In the T2DM subgroup, 65 patients received esaxerenone and 55 received an ARB. In the non-T2DM subgroup, 135 and 145 patients received these treatments, respectively. The least squares mean change from baseline at the\u00a0end of treatment in morning home systolic blood pressure in the T2DM subgroup was \u221210.9 (95% confidence interval \u221213.5, \u22128.4) mmHg in esaxerenone-treated patients and \u22128.8 (\u221211.5, \u22126.0) mmHg in ARB-treated patients; in the non-T2DM subgroup, these were \u221210.5 (\u221212.3, \u22128.7) mmHg and \u22129.1 (\u221210.8, \u22127.3) mmHg, respectively. Although this subgroup analysis was not powered to formally demonstrate non-inferiority, the between-treatment differences in morning home SBP were consistent with the non-inferiority of esaxerenone to ARBs based on the margin used in the primary analysis in both the T2DM and non-T2DM subgroups. Urinary albumin-to-creatinine ratio (UACR) significantly decreased in esaxerenone-treated patients with T2DM (\u221233.4%), but not in those without T2DM. In contrast, UACR significantly decreased in ARB-treated patients without T2DM (\u221221.2%), but not in those with T2DM. One esaxerenone-treated patient in the non-T2DM subgroup had a serum potassium level \u22656.0 mEq\/L, and a low proportion of esaxerenone-treated patients in the non-T2DM subgroup had hypokalemia (2.2%). Overall, this subgroup analysis showed favorable antihypertensive and kidney-protective effects (based on UACR) of esaxerenone, combined with an acceptable safety profile, in patients with hypertension. Moreover, antihypertensive effects were observed regardless of T2DM status, supporting the use of esaxerenone in older patients with hypertension and comorbid T2DM.<\/jats:p>","DOI":"10.1038\/s41440-026-02779-2","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:01:48Z","timestamp":1791586908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of esaxerenone versus angiotensin II receptor blockers in older patients with hypertension, with and without type 2 diabetes mellitus: a predefined subgroup analysis of the ESCORT-HT study"],"prefix":"10.1038","author":[{"given":"Mitsuru","family":"Ohishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ohbayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Abiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kodono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Shimosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Shiosakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketoshi","family":"Furugori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ESCORT-HT investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"2779_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - Global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107\u201311.","journal-title":"J Epidemiol Glob Health"},{"key":"2779_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.arr.2016.01.007","volume":"26","author":"TW Buford","year":"2016","unstructured":"Buford TW. Hypertension and aging. Ageing Res Rev. 2016;26:96\u2013111.","journal-title":"Ageing Res Rev"},{"key":"2779_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11886-021-01443-0","volume":"23","author":"B Alencherry","year":"2021","unstructured":"Alencherry B, Laffin LJ. Treatment of hypertension in patients with diabetes mellitus: a contemporary approach. Curr Cardiol Rep. 2021;23:14.","journal-title":"Curr Cardiol Rep"},{"key":"2779_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434\u201344.","journal-title":"Diabetes Care"},{"key":"2779_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"2779_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41440-022-01136-3","volume":"46","author":"S Hata","year":"2023","unstructured":"Hata S, Ushigome E, Hosomi Y, Yoshimura T, Takegami M, Kitagawa N, et al. Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study. Hypertens Res. 2023;46:565\u201374.","journal-title":"Hypertens Res"},{"key":"2779_CR7","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/HYPERTENSIONAHA.123.20954","volume":"80","author":"Q Yang","year":"2023","unstructured":"Yang Q, Zheng R, Wang S, Zhu J, Li M, Wang T, et al. Systolic blood pressure control targets to prevent major cardiovascular events and death in patients with type 2 diabetes: a systematic review and network meta-analysis. Hypertension. 2023;80:1640\u201353.","journal-title":"Hypertension"},{"key":"2779_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diab Endocrinol. 2022;10:645\u201354.","journal-title":"Lancet Diab Endocrinol"},{"key":"2779_CR9","unstructured":"Japanese Society of Hypertension Guidelines Committee. The Japanese Society of Hypertension guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Tokyo; Life Science Publishing Co., Ltd; 2025."},{"key":"2779_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jch.12733","volume":"18","author":"K Kario","year":"2016","unstructured":"Kario K, Hoshide S. Age- and sex-related differences in efficacy with an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensive patients. J Clin Hypertens. 2016;18:672\u20138.","journal-title":"J Clin Hypertens"},{"key":"2779_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jdi.12629","volume":"8","author":"LJ Sun","year":"2017","unstructured":"Sun LJ, Sun YN, Shan JP, Jiang GR. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. J Diab Investig. 2017;8:609\u201318.","journal-title":"J Diab Investig"},{"key":"2779_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jchf.2019.08.017","volume":"7","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Rossello X, Eschalier R, McMurray JJV, Pocock S, Girerd N, et al. MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPHASIS-HF, and TOPCAT. JACC Heart Fail. 2019;7:1012\u201321.","journal-title":"JACC Heart Fail"},{"key":"2779_CR13","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1007\/s12325-023-02633-8","volume":"40","author":"H Motoki","year":"2023","unstructured":"Motoki H, Inobe Y, Fukui T, Iwasaki A, Hiramitsu S, Koyama S, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetes mellitus undergoing treatment with sodium-glucose cotransporter 2 inhibitors (EAGLE-DH). Adv Ther. 2023;40:5055\u201375.","journal-title":"Adv Ther"},{"key":"2779_CR14","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dose esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"2779_CR15","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2779_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","volume":"25","author":"S Ito","year":"2021","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. Clin Exp Nephrol. 2021;25:1070\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2779_CR17","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. EXCITE-HT investigators. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2779_CR18","doi-asserted-by":"crossref","unstructured":"Kario K, Ohbayashi H, Ishii H, Kato M, Nozaki M, Abiru N, et al. Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: the randomized, open-label ESCORT-HT study. Hypertens Res. 2026;49:2240\u201352.","DOI":"10.1038\/s41440-026-02634-4"},{"key":"2779_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41440-025-02437-z","volume":"49","author":"M Ohishi","year":"2026","unstructured":"Ohishi M, Kario K, Katsuya T, Shimosawa T, Shiosakai K, Furugori T, et al. EXCITE-HT investigators. Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study. Hypertens Res. 2026;49:444\u201356.","journal-title":"Hypertens Res"},{"key":"2779_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14947","volume":"27","author":"K Kario","year":"2025","unstructured":"Kario K, Katsuya T, Shimosawa T, Taguchi T, Tanabe A, Ohishi M. ESCORT-HT investigators. Rationale and design of a randomized, open-label, parallel-group study of esaxerenone versus angiotensin receptor blockers in older patients with uncontrolled hypertension on calcium channel blocker monotherapy (ESCORT-HT). J Clin Hypertens. 2025;27:e14947.","journal-title":"J Clin Hypertens"},{"key":"2779_CR21","unstructured":"Esaxerenone (Minnebro) Tablets [Japanese package insert] [In Japanese], Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2024, https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070243.pdf."},{"key":"2779_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"2779_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41440-024-02078-8","volume":"48","author":"K Kario","year":"2025","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. EXCITE-HT investigators. Home blood pressure-lowering effect of esaxerenone vs trichlormethiazide for uncontrolled hypertension: a prespecified subanalysis of the EXCITE-HT randomized controlled study by age subgroup. Hypertens Res. 2025;48:1586\u201398.","journal-title":"Hypertens Res"},{"key":"2779_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12882-025-03985-9","volume":"26","author":"P De","year":"2025","unstructured":"De P, Khine MT, Frankel A, Goldet G, Banerjee D, Montero RM, et al. Finerenone in the management of diabetic kidney disease. BMC Nephrol. 2025;26:63.","journal-title":"BMC Nephrol"},{"key":"2779_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/21501327211003683","volume":"12","author":"EA Christofides","year":"2021","unstructured":"Christofides EA, Desai N. Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: addressing the barriers to albuminuria testing. J Primer Care Community Health. 2021;12:21501327211003683.","journal-title":"J Primer Care Community Health"},{"key":"2779_CR26","first-page":"3290","volume":"21","author":"H Zhao","year":"2017","unstructured":"Zhao H, Jiang YF, Zhou XC, Yao L, Chen J, Wang D, et al. An effective indicator in predicting cardiovascular events: urine albumin-to-creatinine ratio. Eur Rev Med Pharm Sci. 2017;21:3290\u20135.","journal-title":"Eur Rev Med Pharm Sci"},{"key":"2779_CR27","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","volume":"36","author":"PM Seferovi\u0107","year":"2015","unstructured":"Seferovi\u0107 PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36:1718\u201327.","journal-title":"Eur Heart J"},{"key":"2779_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660\u201371.","journal-title":"Diabetologia"},{"key":"2779_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72:537\u201348.","journal-title":"Hypertension"},{"key":"2779_CR30","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/life15050741","volume":"15","author":"A Sezai","year":"2025","unstructured":"Sezai A, Abe M, Maruyama T, Taoka M, Sekino H, Tanaka M. A prospective crossover clinical trial of esaxerenone and eplerenone in patients with chronic heart failure complicated by hypertension. Life. 2025;15:741.","journal-title":"Life"},{"key":"2779_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41440-023-01519-0","volume":"47","author":"T Katsuya","year":"2024","unstructured":"Katsuya T, Inobe Y, Uchiyama K, Nishikawa T, Hirano K, Kato M, et al. ENaK investigators. Exploratory study on the relationship between urinary sodium\/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study. Hypertens Res. 2024;47:835\u201348.","journal-title":"Hypertens Res"},{"key":"2779_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41440-025-02412-8","volume":"49","author":"K Kario","year":"2026","unstructured":"Kario K, Ohishi M, Katsuya T, Shimosawa T, Shiosakai K, Furugori T, et al. EXCITE-HT investigators. Effect of N-terminal pro B-type natriuretic peptide levels on the efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of Japanese patients with uncontrolled essential hypertension: a subanalysis of the EXCITE-HT study. Hypertens Res. 2026;49:431\u201343.","journal-title":"Hypertens Res"},{"key":"2779_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial. Circulation. 2022;145:437\u201347.","journal-title":"Circulation"},{"key":"2779_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","volume":"44","author":"H Rakugi","year":"2021","unstructured":"Rakugi H, Yamakawa S, Sugimoto K. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertens Res. 2021;44:371\u201385.","journal-title":"Hypertens Res"},{"key":"2779_CR35","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/jdi.13778","volume":"13","author":"K Shikata","year":"2022","unstructured":"Shikata K, Ito S, Kashihara N, Nangaku M, Wada T, Okuda Y, et al. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter\u20092 inhibitor in patients with diabetic kidney disease: subanalysis of two phase III studies. J Diab Investig. 2022;13:1190\u2013202.","journal-title":"J Diab Investig"},{"key":"2779_CR36","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41440-025-02347-0","volume":"48","author":"H Motoki","year":"2025","unstructured":"Motoki H, Kuwahara K, Uchida HA, Wada J, Kario K, Katsuya T, et al. Efficacy and safety of esaxerenone with and without sodium-glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: a pooled analysis of five clinical studies. Hypertens Res. 2025;48:2924\u201337.","journal-title":"Hypertens Res"},{"key":"2779_CR37","unstructured":"American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes\u20142025. Diabetes Care. 2025;48:S1\u2013S352."},{"key":"2779_CR38","unstructured":"Japan Diabetes Society. Japanese Clinical Practice Guideline for Diabetes 2024. Nankodo; 2024."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02779-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:01:49Z","timestamp":1791586909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02779-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":38,"alternative-id":["2779"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02779-2","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mitsuru Ohishi received honoraria from Daiichi Sankyo Co., Ltd. Kazuomi Kario received honoraria from Daiichi Sankyo Co., Ltd. Hiroyuki Ohbayashi received research funding from Kracie, Ltd. and KYORIN Pharmaceutical Co., Ltd. Tomohiro Katsuya received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma KK, Otsuka Pharmaceutical Co., Ltd., and CureApp, Inc. Tatsuo Shimosawa received research funding from SFM Co. Ltd.; consulting fees from Sekisui Medical Co., Ltd. and EPS Co., Ltd.; and honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma KK, and Otsuka Pharmaceutical Co., Ltd. Kazuhito Shiosakai, Taketoshi Furugori, and Takashi Taguchi are employees of Daiichi Sankyo Co., Ltd. Hajime Ishii, Mitsutoshi Kato, Minoru Nozaki, Norio Abiru, Toshiki Fukui, Kazushi Nomura, Yasushi Fukushima, Naoki Itabashi, Kazuaki Uchiyama, Masafumi Nishizawa, Yoshiki Hata, Noriko Nakamura, Satoshi Kodono, Kunio Hirano had no conflict of interest to be declared.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}